Drug Search Results
More Filters [+]

Peginterferon lambda-1a

Alternative Names: peginterferon lambda-1a, bms-914143, bms 914143, bms914143, peginterferon lambda, PEG-IL-29
Latest Update: 2024-05-23
Latest Update Note: Clinical Trial Update

Product Description

Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain. Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04354259)

Mechanisms of Action: IL29 Agonist,Immunomodulator

Novel Mechanism: Yes

Modality: Coagulation Factor

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Peginterferon lambda-1a

Countries in Clinic: Belgium, Bulgaria, France, Georgia, Germany, Israel, Italy, Moldova, Romania, Spain, Turkey, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Hepatitis A|Hepatitis D|Hepatitis D, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

LIMT-2

P3

Active, not recruiting

Hepatitis D, Chronic

2024-11-03

LIMT-2

P3

Active, not recruiting

Hepatitis A|Hepatitis D

2024-06-15

46%

Recent News Events